Bridge the Gap (BTG) - Black Youth Group (Bridge the Gap)

April 27, 2026 updated by: Tia Tyndal, Children's Hospital Los Angeles

Bridging the Gap: A Collaborative Intervention Group for Black Youth at Risk for Suicide

The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer:

-To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal thoughts and behaviors and increasing protective factors such as hope, positive ethnic identity, and family and peer support.

Participants will be asked to attend 10-week group intervention and complete pre-treatment and post-treatment assessment measures.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90027
        • Recruiting
        • Children's Hospital Los Angeles
        • Contact:
        • Principal Investigator:
          • Tia Tyndal, Ph.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 12-17 years old
  • Identify as Black or African American or being of African descent
  • Have current suicidal ideation or suicidal ideation within the last 30 days
  • Have assent from the adolescent participant and consent from an individual's caregiver or guardian to participate.

Exclusion Criteria:

  • An active psychotic disorder or current psychosis symptoms
  • No history of suicide attempt(s) or suicide ideation in the past 30 days
  • Cognitive deficits or a medical condition diagnosed from a medical provider that precludes full understanding of study materials as assessed through an inability to complete the pre-treatment CAMS SSF & SSP
  • Caregivers, guardians, and/or the patient refuse to participate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment Arm
Participants will complete a 10-week group and complete pre-treatment and post-treatment assessment measures.
Behavioral: Bridge the Gap (BTG) - Black Youth Group
Participants will complete a group intervention, rooted in the Collaborative Assessment & Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Collaborative Assessment & Management of Suicidality - Suicide Status Form (SSF)
Time Frame: From pre-treatment until 3 months post-treatment, approximately 23 weeks.
An assessment of suicide risk that consists of six core assessment constructs: psychological pain, stress, agitation, hopelessness, self-hate, and overall risk of suicide; as well as reasons for living and reasons for dying constructs, and wish to live and wish to die constructs.
From pre-treatment until 3 months post-treatment, approximately 23 weeks.
Ethnic Identity Scale (EIS)
Time Frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 17-item scale that assesses the three components of ethnic identity and distinguishes between exploration, resolution, and affirmation. Scores range from 17-68, with higher scores indicating higher levels of affirmation, exploration, and resolution.
From baseline until 3 months post-treatment, approximately 22 weeks.
Living Ladder Scale
Time Frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A one-item measure that is prospectively associated with suicidal ideation and suicide attempts by measuring readiness to continue living among individuals thinking of suicide. Scores range from 0-8, with 8 indicating an individual is committed to making changes to make their lives worth living.
From baseline until 3 months post-treatment, approximately 22 weeks.
Brief Suicide Cognitions Scale (B-SCS)
Time Frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 6-item self-report scale that measures the suicidal belief system, including dimensions of unlovability, unbearability, and unsolvability. Scores range from 6-30, with lower scores indicating fewer suicide cognitions.
From baseline until 3 months post-treatment, approximately 22 weeks.
Therapeutic Relationship Working Alliance Inventory, Short Revised (WAI-SR)
Time Frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 12-item scale that reflects Bordin's three-dimensional conceptualization of therapeutic alliance: task, goal, and bond. Scores range from 12-60, with higher scores indicating higher therapeutic alliance.
From baseline until 3 months post-treatment, approximately 22 weeks.
Optimism and Hope Scale (OHS)
Time Frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 14-item scale that measures an individual's level of both optimism, as characterized by a positive outlook on the future, and hope, as characterized by the belief in one's ability to achieve goals and navigate challenges. Scores range from 14-56, with lower scores indicating more hope and optimism.
From baseline until 3 months post-treatment, approximately 22 weeks.
Parent Readiness for Hospital Discharge Scale (RHDS)
Time Frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 23-item scale aimed at providing a discharge readiness assessment before pediatric discharge from care in hospital settings. Scores range from 0-80, with higher scores indicating more readiness.
From baseline until 3 months post-treatment, approximately 22 weeks.
Group Cohesion Scale
Time Frame: From baseline until the beginning of post-treatment, approximately 10 weeks.
A 12-item self-report scale that measures group cohesion, including dimensions of engagement, conflict, and avoidance. Scores across the subscales range from 0-72; higher scores indicate more of that dimension.
From baseline until the beginning of post-treatment, approximately 10 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Children's Hospital Los Angeles

Collaborators

American Psychological Foundation

Investigators

  • Principal Investigator: Tia Tyndal, PhD, Children's Hospital Los Angeles

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

March 12, 2025

First Submitted That Met QC Criteria

March 12, 2025

First Posted (Actual)

March 18, 2025

Study Record Updates

Last Update Posted (Actual)

April 30, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHLA-25-00072

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide Prevention

Clinical Trials on Bridge the Gap (BTG) - Black Youth Group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe